RANGE, a phase III, randomized, placebo-controlled, double-blind trial of ramucirumab (RAM) and docetaxel (DOC) in platinum-refractory urothelial carcinoma (UC): Overall survival results

被引：0

作者：

Petrylak, D. P. ^{[1
]}

Sternberg, C. N. ^{[2
]}

Drakaki, A. ^{[3
]}

de Wit, R. ^{[4
]}

Nishiyama, H. ^{[5
]}

Necchi, A. ^{[6
]}

Castellano, D. ^{[7
]}

Bamias, A. ^{[8
]}

Chi, K. N. ^{[9
]}

van der Heijden, M. S. ^{[10
]}

Matsubara, N. ^{[11
]}

Hussain, S. ^{[12
]}

Flechon, A. ^{[13
]}

Alekseev, B. Y. ^{[14
]}

Yu, E. Y. ^{[15
]}

Walgren, R. A. ^{[16
]}

Russo, F. ^{[17
]}

Zimmermann, A. H. ^{[16
]}

Bell-Mcguinn, K. M. ^{[16
]}

Powles, T. B. ^{[18
]}

机构：

[1] Yale Univ, Sch Med, Med Oncol, New Haven, CT USA

[2] Azienda Osped S Camillo Forlanini, Med Oncol, Rome, Italy

[3] Univ Calif Los Angeles, Med Ctr, Med, Los Angeles, CA 90024 USA

[4] Erasmus MC, Med Oncol, Daniel den Hoed Canc Ctr, Rotterdam, Netherlands

[5] Univ Tsukuba, Urol, Tsukuba, Ibaraki, Japan

[6] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy

[7] Univ Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain

[8] Univ Athens, Clin Therapeut, Sotiria Gen Chest Dis Hosp, Athens, Greece

[9] British Columbia Canc Agcy, Med Oncol, Vancouver, BC, Canada

[10] Nederlands Kanker Inst Antoni van Leeuwenhoek NKI, Med Oncol, Amsterdam, Netherlands

[11] Natl Canc Ctr Hosp East, Oncol, Kashiwa, Chiba, Japan

[12] Plymouth Univ, Oncol, Plymouth, Devon, England

[13] Ctr Leon Berard, Med Oncol, Lyon, France

[14] Herzen Canc Res Inst, Oncol, Moscow, Russia

[15] Univ Washington, Med Oncol, Seattle, WA 98195 USA

[16] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA

[17] Eli Lilly & Co, Oncol, Florence, SC USA

[18] St Bartholomews Hosp, Oncol, London, England

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

865PD

引用

页数：2

共 50 条

[21] Re: Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Metastatic Urothelial Carcinoma after Platinum-Based Therapy (RANGE): A Randomised, Double-Blind, Phase 3 Trial
Chang, Sam S.
[J]. JOURNAL OF UROLOGY, 2019, 201 (06) : 1052 - 1053
[22] Re: Efficacy of Everolimus in Advanced Renal Cell Carcinoma: A Double-Blind, Randomized, Placebo-Controlled Phase III Trial
Culp, Stephen H.
Wood, Christopher G.
[J]. EUROPEAN UROLOGY, 2009, 55 (06) : 1484 - 1485
[23] Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
Inman, Robert D.
Davis, John C., Jr.
van der Heijde, Desiree
Dickman, Laura
Sieper, Joachim
Kim, Sung Il
Mack, Michael
Han, John
Visvanathan, Sudha
Xu, Zhenhua
Su, Benjamin
Beutler, Anna
Braun, Juergen
[J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (11): : 3402 - 3412
[24] Venlafaxine in fibromyalgia: Results of a randomized, placebo-controlled, double-blind trial.
Zijlstra, TR
Barendregt, PJ
van De Laar, MAF
[J]. ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S105 - S105
[25] A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401
Kelly, W. K.
Halabi, S.
Carducci, M. A.
George, D. J.
Mahoney, J. F.
Stadler, W. M.
Morris, M. J.
Kantoff, P. W.
Monk, J. P., III
Small, E. J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
[26] A Randomized Double-Blind Placebo-Controlled Phase III Trial of Selegiline Monotherapy for Early Parkinson Disease
Mizuno, Yoshikuni
Hattori, Nobutaka
Kondo, Tomoyoshi
Nomoto, Masahiro
Origasa, Hideki
Takahashi, Ryosuke
Yamamoto, Mitsutoshi
Yanagisawa, Nobuo
[J]. CLINICAL NEUROPHARMACOLOGY, 2017, 40 (05) : 201 - 207
[27] Phase III randomized, double-blind, placebo-controlled trial of donepezil in irradiated brain tumor survivors
Rapp, Stephen R.
Case, Doug
Peiffer, Ann
Naughton, Michelle Joy
Stieber, Volker W.
Bayer, Gerald K.
Bilodeau, Paul A.
Moore, Dennis Frederic
Falchuk, Steven Charles
Needles, Burton M.
Piephoff, James
Edenfield, William J.
Giguere, Jeffrey K.
Erickson, Nicholette
Loghin, Monica Elena
Shaw, Edward G.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[28] GLANCE Results of a phase 2, randomized, double-blind, placebo-controlled study
Goodman, A. D.
Rossman, H.
Bar-Or, A.
Miller, A.
Miller, D. H.
Schmierer, K.
Lublin, F.
Khan, O.
Bormann, N. M.
Yang, M.
Panzara, M. A.
Sandrock, A. W.
[J]. NEUROLOGY, 2009, 72 (09) : 806 - 812
[29] Efficacy and safety of oxycodone DETERx: results of a randomized, double-blind, placebo-controlled phase III study
Kopecky, E.
O'Connor, M.
Varanasi, R.
Saim, S.
Fleming, A.
[J]. JOURNAL OF PAIN, 2015, 16 (04) : S87 - S87
[30] SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
Zhu, Andrew X.
Rosmorduc, Olivier
Evans, T. R. Jeffry
Ross, Paul J.
Santoro, Armando
Carrilho, Flair Jose
Bruix, Jordi
Qin, Shukui
Thuluvath, Paul J.
Llovet, Josep M.
Leberre, Marie-Aude
Jensen, Markus
Meinhardt, Gerold
Kang, Yoon-Koo
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (06) : 559 - 566

← 1 2 3 4 5 →